Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood blood.2024025366.

https://doi.org/10.1182/blood.2024025366

Published: 2024

Includes: Supplemental data

Journal Articles

CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models

Berit J. Brinkmann, Alessia Floerchinger, Christina Schniederjohann, Tobias Roider, Mariana Coelho, Norman Mack, Peter-Martin Bruch, Nora Liebers, Sarah Dötsch, Dirk H. Busch, Michael Schmitt, Frank Neumann, Philipp M. Roessner, Martina Seiffert, Sascha Dietrich

Blood (2024) 144 (7): 784–789.

https://doi.org/10.1182/blood.2023022682

Published: 2024

Includes: Supplemental data

Journal Articles

The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature

Anna Mathioudaki, Xizhe Wang, David Sedloev, Richard Huth, Aryan Kamal, Michael Hundemer, Yi Liu, Spyridoula Vasileiou, Premal Lulla, Carsten Müller-Tidow, Peter Dreger, Thomas Luft, Tim Sauer, Michael Schmitt, Judith B. Zaugg, Caroline Pabst

Blood (2024) 143 (13): 1269–1281.

https://doi.org/10.1182/blood.2023021815

Published: 2024

Includes: Supplemental data

Journal Articles

The Ig Superfamily Ligand B7H6 Subjects Activated T Cells to NK Cell Surveillance and Limits CAR T Cell Persistence

Blood (2023) 142 (Supplement 1): 4830.

https://doi.org/10.1182/blood-2023-190873

Published: 2023

Journal Articles

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

Julia M. Unglaub, Berit Brinkmann, Qian Chen, David Sedloev, Peter-Martin Bruch, Carolin Kolb, Volker Eckstein, Yi Liu, Anita Schmitt, Simon Raffel, Michael Schmitt, Carsten Müller-Tidow, Junyan Lu, Sascha Dietrich, Tim Sauer

Blood (2023) 142 (Supplement 1): 5969.

https://doi.org/10.1182/blood-2023-181251

Published: 2023

Journal Articles

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Blood (2022) 140 (4): 349–358.

https://doi.org/10.1182/blood.2021015209

Published: 2022

Includes: Supplemental data

Journal Articles

Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Blood (2021) 138 (Supplement 1): 3822.

https://doi.org/10.1182/blood-2021-146120

Published: 2021

Journal Articles

First-in-Human Study of WT1 Recombinant Protein Vaccination in Elderly Patients with AML in Remission: A Single-Center Experience

Stefanie Kreutmair, Dietmar Pfeifer, Miguel Waterhouse, Konstanze Döhner, Anna Frey, Justus Duyster, Anna Lena Illert, Michael Schmitt, Michael Lübbert

Blood (2021) 138 (Supplement 1): 1278.

https://doi.org/10.1182/blood-2021-150082

Published: 2021

Journal Articles

Easix before Conditioning Therapy Predicts Sepsis after Allogeneic Stem Cell Transplantation

Felix Korell, Nicholas Schreck, Axel Benner, Tobias Liebregts, Stefan Schönland, Ute Hegenbart, Aleksandar Radujkovic, Michael Schmitt, Peter Dreger, Thomas Luft

Blood (2021) 138 (Supplement 1): 1774.

https://doi.org/10.1182/blood-2021-153104

Published: 2021

Journal Articles

Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD)

Yuntian Ding, Lei Wang, Ming Ni, Wenjie Gong, Sanmei Wang, Brigitte Neuber, Maria-Luisa Schubert, Tim Sauer, Angela Hückelhoven-Krauss, Thomas Luft, Ute Hegenbart, Stefan Schönland, Volker Eckstein, Jishi Wang, William Hermann Krüger, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt

Blood (2021) 138 (Supplement 1): 1810.

https://doi.org/10.1182/blood-2021-150106

Published: 2021

Journal Articles

Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Maria-Luisa Schubert, Anita Schmitt, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, Birgit Michels, Philip Waldhoff, Leopold Sellner, Felix Korell, Susanne Hofmann, Petra Pavel, Anthony D Ho, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt

Blood (2021) 138 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2021-152028

Published: 2021

Journal Articles

Easix Predicts Severe Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neuro-Toxicity Syndrome (ICANS) in Patients Receiving CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy

Felix Korell, Olaf Penack, Michael Schmitt, Carsten Müller-Tidow, Lars Bullinger, Peter Dreger, Thomas Luft

Blood (2021) 138 (Supplement 1): 3861.

https://doi.org/10.1182/blood-2021-152875

Published: 2021

Journal Articles

Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy

Felix Korell, Maria-Luisa Schubert, Tim Sauer, Anita Schmitt, Patrick Derigs, Tim Frederik Weber, Paul Schnitzler, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt

Blood (2021) 138 (Supplement 1): 4835.

https://doi.org/10.1182/blood-2021-149743

Published: 2021

Journal Articles

The First Real-World Experience with Betibeglogene Autotemcel (beti-cel) Gene Therapy Treatment for Transfusion-Dependent β-Thalassemia (TDT)

Joachim B. Kunz, Eva Roth, Adil Mirza, Johann Greil, Petra Pavel, Anita Schmitt, Michael Schmitt, Alexander Kunz, Andreas E. Kulozik

Blood (2021) 138 (Supplement 1): 4917.

https://doi.org/10.1182/blood-2021-148460

Published: 2021

Journal Articles

The Decrease of Anti-CD3 Antibody Concentration Improved the Cytotoxicity of Chimeric Antigen Receptor (CAR) T Cells in the Treatment of Chronic Lymphoblastic Leukemia (CLL)

Sanmei Wang, Yilian Yang, Yu Zhu, Lei Fan, Michael Schmitt, Maria Luisa Schubert, Jianyong Li

Blood (2021) 138 (Supplement 1): 4792.

https://doi.org/10.1182/blood-2021-150661

Published: 2021

Journal Articles

CD19.CAR-T Cell Analysis Using Flow Cytometry and PCR

Nicola Schanda, Alexander Kunz, Tim Sauer, Maria-Luisa Schubert, Felix Korell, Angela Hückelhoven-Krauss, Brigitte Neuber, Mandy Hinkelbein, Carsten Müller-Tidow, Michael Schmitt, Anita Schmitt

Blood (2021) 138 (Supplement 1): 4797.

https://doi.org/10.1182/blood-2021-152955

Published: 2021

Journal Articles

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

Tim Sauer, Kathan Parikh, Sandhya Sharma, Bilal Omer, David Sedloev, Qian Chen, Linus Angenendt, Christoph Schliemann, Michael Schmitt, Carsten Müller-Tidow, Stephen Gottschalk, Cliona M. Rooney

Blood (2021) 138 (4): 318–330.

https://doi.org/10.1182/blood.2020008221

Published: 2021

Includes: Supplemental data

Journal Articles

Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells

Viktoria Blumenberg, MD, Maria-Luisa Schubert, MD, Eli Zamir, Sabine Schmidt, Roman Rohrbach, Philipp Waldhoff, Daria Bozic, Hendrik Pock, MD, Eran Elinav, Christian Schmidt, MD, Veit Buecklein, MD, Carsten Müller-Tidow, MD, Peter Dreger, MD, Michael von Bergwelt, MD PhD, Michael Schmitt, MD, Marion Subklewe, MD, Christoph Stein-Thöringer, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-141210

Published: 2020

Journal Articles

Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)

Felix Korell, MD, Thomas Luft, MD, PhD, Michael Schmitt, MD, Sascha Dietrich, MD, Anita Schmitt, MD, Carsten Mueller-Tidow, MD, Peter Dreger, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139615

Published: 2020

Journal Articles

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Mingya Yang, MD, Lei Wang, MD, Ming Ni, Maria-Luisa Schubert, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Ruben A. Gößmann, Christian Kleist, Volker Eckstein, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD, Anita Schmitt, MD

Blood (2019) 134 (Supplement_1): 5620.

https://doi.org/10.1182/blood-2019-125622

Published: 2019

NARROW

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models

The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature

The Ig Superfamily Ligand B7H6 Subjects Activated T Cells to NK Cell Surveillance and Limits CAR T Cell Persistence

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

First-in-Human Study of WT1 Recombinant Protein Vaccination in Elderly Patients with AML in Remission: A Single-Center Experience

Easix before Conditioning Therapy Predicts Sepsis after Allogeneic Stem Cell Transplantation

Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD)

Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Easix Predicts Severe Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neuro-Toxicity Syndrome (ICANS) in Patients Receiving CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy

Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy

The First Real-World Experience with Betibeglogene Autotemcel (beti-cel) Gene Therapy Treatment for Transfusion-Dependent β-Thalassemia (TDT)

The Decrease of Anti-CD3 Antibody Concentration Improved the Cytotoxicity of Chimeric Antigen Receptor (CAR) T Cells in the Treatment of Chronic Lymphoblastic Leukemia (CLL)

CD19.CAR-T Cell Analysis Using Flow Cytometry and PCR

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells

Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only